Kedrion weighs €2bn debt raise to shareholder dividend
Kedrion Biopharma is exploring a debt financing of around €2bn that could be used in part to fund a dividend payment to its shareholders, according to a report by Bloomberg citing unnamed people familiar with the matter.
Kedrion Biopharma is reportedly considering a €2 billion debt financing, which could be used to fund shareholder dividends, according to Bloomberg. Italian blood plasma therapies specialist Kedrion has been talking to private credit lenders about potential financing, though a transaction has not been finalized and the company could still choose not to raise the debt.
The talks are confidential, and unnamed sources spoke to Bloomberg on the condition of anonymity. Kedrion, acquired by Permira and a group of co-investors in 2022, is looking to raise the debt amid a relatively quiet M&A market. This potential transaction showcases how private equity-backed companies are turning to debt markets to return capital to shareholders while continuing to support growth. Permira and Kedrion have both declined to comment on the matter.
Written by urgent.news from Private Equity Wire's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
